8-K: USANA Health Sciences Secures New $75 Million Revolving Credit Facility, with Option for Additional $200 Million

USANA Health Sciences, Inc. has entered into a Third Amended and Restated Credit Agreement providing a $75 million revolving credit facility, with an option to increase by an additional $200 million, maturing in June 2030.

Summary

• USANA Health Sciences, Inc. (the Company) and certain material subsidiaries have entered into a Third Amended and Restated Credit Agreement with Bank of America, N.A., effective June 27, 2025.
• The agreement establishes a revolving credit limit for loans to the Company of up to $75 million.
• The Company has the option to request an increase in the aggregate commitment under the Credit Facility by up to an additional $200 million, potentially bringing the total facility to $275 million.
• The Credit Facility matures on June 27, 2030.
• Obligations under the Credit Agreement are secured by the pledge of capital stock of the Company's subsidiaries, pursuant to an Amended and Restated Security and Pledge Agreement.
• Interest on revolving borrowings will be based on Term SOFR, Base Rate, or Daily Simple SOFR, plus an applicable margin, and for Swingline Loans, Base Rate plus an applicable margin.
• The Company is required to maintain a consolidated EBITDA of at least $80 million for the four prior fiscal quarters ending June 28, 2025, September 27, 2025, January 3, 2026, April 4, 2026, and July 4, 2026.
• The consolidated EBITDA covenant increases to at least $100 million for the four prior fiscal quarters ending October 3, 2026, and each fiscal quarter thereafter.
• The Company must maintain a consolidated funded debt to consolidated EBITDA ratio equal to or less than 2.0 to 1.0, commencing with the fiscal quarter ending June 28, 2025.
• The Credit Agreement does not include any restrictions on the payment of cash dividends or share repurchases by the Company.

Sentiment

Score: 7

Explanation: The new credit agreement provides significant liquidity and financial flexibility, with favorable terms like no dividend restrictions. While the financial covenants are standard, the increasing EBITDA requirement could be a future challenge if growth slows. Overall, it's a positive, routine financial update for a stable company.

Positives

• Secured a new revolving credit facility of $75 million, providing enhanced liquidity and financial flexibility for general corporate purposes and Permitted Acquisitions.
• Includes an option to increase the aggregate commitment by up to an additional $200 million, allowing for significant future capital access without needing a new agreement.
• The credit facility has a favorable five-year maturity date of June 27, 2030, providing long-term financing stability.
• The agreement explicitly states no restrictions on the payment of cash dividends or share repurchases, offering flexibility for capital allocation to shareholders.

Negatives

• The financial covenants, particularly the increasing consolidated EBITDA requirement (from $80 million to $100 million), could become challenging if the company's financial performance does not meet these targets.
• The variable interest rates (Term SOFR, Base Rate, Daily Simple SOFR) expose the company to potential increases in borrowing costs if market rates rise.
• Failure to comply with any of the financial covenants or other terms of the agreement could lead to an Event of Default, resulting in immediate acceleration of all outstanding amounts and termination of commitments.

Risks

• Financial Covenant Breach: Failure to maintain the required consolidated EBITDA or consolidated funded debt to consolidated EBITDA ratio could trigger an Event of Default.
• Interest Rate Risk: The variable interest rates on borrowings expose the Company to fluctuations in market interest rates, potentially increasing financing costs.
• Default and Remedies: Customary events of default, including non-payment, covenant breaches, and insolvency, could lead to the Administrative Agent declaring all amounts immediately due and payable, terminating commitments, and exercising remedies against the collateral.
• Collateral Pledge: The obligations are secured by a pledge of capital stock of material subsidiaries, meaning these assets could be subject to seizure by the Administrative Agent in the event of a default.
• Environmental Liabilities: Undisclosed or future environmental liabilities could result in significant costs or fines, potentially having a Material Adverse Effect.
• Litigation Risk: Pending or threatened litigation or regulatory matters, if material, could adversely impact the Company's financial condition or operations.
• ERISA Events: The occurrence of an ERISA Event with a liability exceeding $30,000,000 could constitute an Event of Default.
• Sanctions and Anti-Corruption Laws: Non-compliance with applicable Sanctions or Anti-Corruption Laws could lead to legal penalties, fines, or reputational damage.

Future Outlook

The new credit agreement provides USANA Health Sciences with enhanced financial flexibility and liquidity, supporting future strategic initiatives such as Permitted Acquisitions and general corporate purposes. The option to increase the facility by an additional $200 million suggests a proactive approach to potential future capital needs and growth opportunities.

Management Comments

• The Company's management, through its Responsible Officers, represents and warrants that the conditions for credit extensions are satisfied at the time of each borrowing.
• The Company's management, through its Responsible Officers, confirms that the information provided in loan notices and swingline loan notices complies with the requirements of the Credit Agreement.
• The Company ratifies and confirms the Master Guaranty, indicating ongoing commitment to existing guarantee arrangements.

Industry Context

The securing of a new credit facility is a standard practice for publicly traded companies to manage liquidity and fund operations or growth. The terms, including the revolving nature and option for increase, are typical for established companies seeking flexible financing. The financial covenants (EBITDA and Debt-to-EBITDA) are common metrics used by lenders to assess a company's financial health and repayment capacity, aligning with general industry lending standards. The absence of restrictions on dividends and share repurchases indicates a degree of financial strength and confidence from the lender, which is a positive signal within the consumer health and direct selling industries.

Comparison to Industry Standards

• The $75 million revolving credit facility, with an option for an additional $200 million, represents a substantial credit line, indicating strong lender confidence in USANA Health Sciences' financial stability and future prospects, comparable to facilities secured by other mid-to-large cap companies in the health and nutrition industry.
• The financial covenants, specifically the consolidated EBITDA and debt-to-EBITDA ratio, are standard for corporate credit facilities. A maximum debt-to-EBITDA ratio of 2.0x is generally considered healthy and manageable within the consumer health and direct selling industries, suggesting a conservative leverage profile compared to some peers.
• The flexibility regarding dividends and share repurchases is a favorable term, often seen in agreements with financially sound companies, allowing management discretion in capital allocation for shareholder returns, unlike more restrictive agreements sometimes imposed on companies with higher leverage or perceived risk.
• The five-year maturity (June 2030) is a typical duration for revolving credit facilities, providing medium-term financial stability consistent with industry norms.

Management Changes

Corporate Governance

Legal Proceedings

• No actions, suits, proceedings, claims or disputes are pending or, to the knowledge of the Loan Parties, threatened or contemplated, that could reasonably be expected to have a Material Adverse Effect.
• An Event of Default can be triggered if one or more final judgments or orders for the payment of money exceeding $30,000,000 (to the extent not covered by independent third-party insurance) are entered against any Loan Party or Subsidiary, or if non-monetary final judgments have a Material Adverse Effect.

Related Party Transactions

• Transactions with officers, directors, or affiliates are permitted if they are in the ordinary course of business on fair and reasonable terms, substantially as favorable as would be obtainable in a comparable arms-length transaction with a non-affiliate.
• This restriction does not apply to transactions between or among the Borrower and any of its wholly-owned Subsidiaries or between and among any wholly-owned Subsidiaries.

Stakeholder Impact

• Shareholders: The absence of restrictions on cash dividends and share repurchases is positive, allowing for potential returns. The new credit facility provides financial stability, which can be viewed favorably. However, failure to meet financial covenants could negatively impact share price and future access to capital.
• Employees: No direct impact mentioned, but a stable financial position generally supports employment stability.
• Customers/Suppliers: No direct impact mentioned. Stable financing can indirectly ensure continued operations and supply chain reliability.
• Creditors (Lenders): The new agreement provides a clear framework for the credit facility, including security interests and financial covenants, enhancing the security for the lenders.

Next Steps

• The Company will continue to comply with the financial covenants, including maintaining specified consolidated EBITDA and consolidated funded debt to consolidated EBITDA ratios.
• The Company may, at its option and subject to conditions, request to increase the aggregate commitment under the Credit Facility by up to $200 million.
• The Company will continue to deliver financial statements and other information to the Administrative Agent and Lenders as required by the agreement.
• The Company will ensure all new material domestic subsidiaries become guarantors and pledge their equity interests.

Key Dates

Recommendation

Keywords

Revolving Credit Facility, Debt Financing, SEC Filing, 8-K, USANA Health Sciences, Bank of America, Financial Covenants, EBITDA, Debt-to-EBITDA Ratio, Corporate Debt, Liquidity, Capital Management, Share Repurchases, Dividends, Corporate Governance, Risk Management, Nutraceuticals, Direct Selling